Comprehensive characterization of alternative splicing in renal cell carcinoma
暂无分享,去创建一个
Mugen Liu | Ke Chen | Heng Li | Yangjun Zhang | Xiaoliang Wu | Jingzhen Li | Kui Sun | Libin Yan | Chen Duan | Haoran Liu | Zhangqun Ye | Hua Xu | Mugen Liu | Z. Ye | Hua Xu | Heng Li | Ke Chen | Libin Yan | Jingzhen Li | Yangjun Zhang | Haoran Liu | C. Duan | Xiaoliang Wu | Kui Sun
[1] S. Miyano,et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome , 2014, Nature Communications.
[2] Olga Tanaseichuk,et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.
[3] R. Gibbs,et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. , 2018, Cell reports.
[4] Begoña Aguado,et al. Global variability in gene expression and alternative splicing is modulated by mitochondrial content , 2015, Genome research.
[5] Alan Hall,et al. The cytoskeleton and cancer , 2009, Cancer and Metastasis Reviews.
[6] Robert Brown,et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer , 2015, Nucleic Acids Res..
[7] Satoru Miyano,et al. A comprehensive characterization of cis-acting splicing-associated variants in human cancer. , 2018, Genome research.
[8] J. Reeves,et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.
[9] Ping-Chih Ho,et al. Immunity, Hypoxia and Metabolism - the ménage à trois of cancer: implications for immunotherapy. , 2019, Physiological reviews.
[10] A. Gonzalez-Perez,et al. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations , 2017, Clinical Cancer Research.
[11] John N. Weinstein,et al. SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts , 2012, Bioinform..
[12] S. Taverna,et al. SETD5 Regulates Chromatin Methylation State and Preserves Global Transcriptional Fidelity during Brain Development and Neuronal Wiring , 2019, Neuron.
[13] Hunter N B Moseley,et al. GOcats: A tool for categorizing Gene Ontology into subgraphs of user-defined concepts , 2020, PloS one.
[14] Dmitri D. Pervouchine,et al. Integrative transcriptomic analysis suggests new autoregulatory splicing events coupled with nonsense-mediated mRNA decay , 2019, Nucleic acids research.
[15] G. Altavilla,et al. Natural killer cells infiltrating human nonsmall‐cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells , 2008, Cancer.
[16] M. J. Kim,et al. ICAM-3-induced cancer cell proliferation through the PI3K/Akt pathway. , 2006, Cancer letters.
[17] Z. Ye,et al. Pan-cancer analysis of clinical relevance of alternative splicing events in 31 human cancers , 2019, Oncogene.
[18] A. Dopazo,et al. Transcriptional expression of cis‐acting and trans‐acting splicing mutations cause autosomal dominant retinitis pigmentosa , 2008, Human mutation.
[19] Guo Ci Teo,et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.
[20] L. Duret,et al. The fitness cost of mis-splicing is the main determinant of alternative splicing patterns , 2017, Genome Biology.
[21] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[22] Helga Thorvaldsdóttir,et al. Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..
[23] L. Saal,et al. Features of increased malignancy in eosinophilic clear cell renal cell carcinoma , 2020, The Journal of pathology.
[24] H. Kume,et al. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma , 2016, Cancer Immunology Research.
[25] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[26] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.
[27] Antonio Lopez-Beltran,et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. , 2015, European urology.
[28] Ludmila V. Danilova,et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.
[29] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[30] Jiwei Zhang,et al. Genome‐wide analysis reveals that exon methylation facilitates its selective usage in the human transcriptome , 2018, Briefings Bioinform..
[31] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[32] Brian Craft,et al. Visualizing and interpreting cancer genomics data via the Xena platform , 2020, Nature Biotechnology.
[33] Patrick Flick,et al. GOATOOLS: A Python library for Gene Ontology analyses , 2018, Scientific Reports.
[34] D. Black,et al. Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers , 2020, Proceedings of the National Academy of Sciences.
[35] T. Willnow,et al. Endocytic receptor LRP2/megalin—of holoprosencephaly and renal Fanconi syndrome , 2017, Pflügers Archiv - European Journal of Physiology.
[36] E. Jaffee,et al. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.
[37] Nicholas J. McGlincy,et al. Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense? , 2008, Trends in biochemical sciences.
[38] B. Rini,et al. Renal cell carcinoma , 2009, The Lancet.
[39] Amber C. Donahue,et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial , 2020, Nature Medicine.
[40] B. Delahunt,et al. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[41] Christopher B. Burge,et al. Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing Signals , 2004, J. Comput. Biol..
[42] M. Ares,et al. Context-dependent control of alternative splicing by RNA-binding proteins , 2014, Nature Reviews Genetics.
[43] Lawrence A. Donehower,et al. The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.
[44] Xiaohui Sun,et al. Genome-wide analysis reveals the association between alternative splicing and DNA methylation across human solid tumors , 2020, BMC Medical Genomics.
[45] Shan Jiang,et al. ICAM3 mediates inflammatory signaling to promote cancer cell stemness. , 2018, Cancer letters.
[46] Delong Liu,et al. Syk inhibitors in clinical development for hematological malignancies , 2017, Journal of Hematology & Oncology.
[47] Karine Tremblay,et al. Alternative splicing of SYK regulates mitosis and cell survival , 2011, Nature Structural &Molecular Biology.
[48] J. Kinney,et al. Quantitative Activity Profile and Context Dependence of All Human 5' Splice Sites. , 2018, Molecular cell.
[49] Nan Yang,et al. CancerSplicingQTL: a database for genome-wide identification of splicing QTLs in human cancer , 2018, Nucleic Acids Res..
[50] Christopher M. Fife,et al. Movers and shakers: cell cytoskeleton in cancer metastasis , 2014, British journal of pharmacology.